Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression
Authors
Keywords
NK cells, Pancreatic cancer, Carcinomas, Cytotoxicity, Flow cytometry, Cancer treatment, Cytokines, Breast cancer
Journal
PLoS One
Volume 13, Issue 12, Pages e0200664
Publisher
Public Library of Science (PLoS)
Online
2019-01-01
DOI
10.1371/journal.pone.0200664
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
- (2016) Guoqing Ouyang et al. World Journal of Surgical Oncology
- How Do Cytotoxic Lymphocytes Kill Cancer Cells?
- (2015) L. Martinez-Lostao et al. CLINICAL CANCER RESEARCH
- Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
- (2015) Silvia Boero et al. Journal of Translational Medicine
- Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
- (2015) Eric Assenat et al. Oncotarget
- Paclitaxel Enhances Antibody-dependent Cell-mediated Cytotoxicity of Trastuzumab by Rapid Recruitment of Natural Killer Cells in HER2-positive Breast Cancer
- (2014) Daishu Miura et al. JOURNAL OF NIPPON MEDICAL SCHOOL
- Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma
- (2013) Tomar Ghansah et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
- (2013) Hideki Ueno et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
- (2013) Branka Petricevic et al. Journal of Translational Medicine
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and molecular characterization of HER2 amplified-pancreatic cancer
- (2013) Angela Chou et al. Genome Medicine
- Gastric cancer and trastuzumab: first biologic therapy in gastric cancer
- (2013) Krishna S. Gunturu et al. Therapeutic Advances in Medical Oncology
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
- (2012) J Harder et al. BRITISH JOURNAL OF CANCER
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
- (2012) Roch Houot et al. OncoImmunology
- Pancreatic cancer
- (2011) Audrey Vincent et al. LANCET
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
- (2010) Jason A Wilken et al. Journal of Ovarian Research
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- HER2 overexpression correlates with survival after curative resection of pancreatic cancer
- (2009) Masahiro Komoto et al. CANCER SCIENCE
- Monoclonal antibodies for cancer immunotherapy
- (2009) Louis M Weiner et al. LANCET
- Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies
- (2008) W. Lin et al. BLOOD
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search